A notable trend observed in this analysis was the decline in phase 1–4 trials and the increase in trials without FDA-defined phases, indicated as “Phase N/A” in ClinicalTrials.gov.
← all excerpts
Update on the clinical trial landscape: analysis of ClinicalTrials.gov registration data, 2000-2020.
1
—
—